Pompe Program Update

Category: Archive
February 25, 2006

As the new year begins, 2006 promises to be a dynamic time for the Pompe community. The first half of the year is expected to bring responses from both the FDA and the European Medicines Agency (EMEA) on the regulatory filings for Myozyme.  The Late-Onset Treatment Study is approximately 2/3 enrolled at this time and over 200 patients worldwide are receiving the investigational rhGAA enzyme treatment.

Download Program Update (wrong link / document missing)

Back to news articles